SEC Tracker
Get the app

Retension Pharmaceuticals RTSN

Retension Pharmaceuticals appoints new CFO

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Robert Wong appointed as VP, Chief Accounting Officer effective Nov 2, 2026
  2. Annual base salary of $360,000 and 30% discretionary bonus target
  3. Stock option award of 25,000 shares with 25% vesting after 1 year

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Retension Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX